HomeCompareCCGY vs ABBV

CCGY vs ABBV: Dividend Comparison 2026

CCGY yields 2000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCGY wins by $1.6247481716182984e+23M in total portfolio value
10 years
CCGY
CCGY
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full CCGY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CCGY vs ABBV

📍 CCGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCGYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCGY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCGY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCGY
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CCGY beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCGY + ABBV for your $10,000?

CCGY: 50%ABBV: 50%
100% ABBV50/50100% CCGY
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCGY
No analyst data
Altman Z
3.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCGY buys
0
ABBV buys
0
No recent congressional trades found for CCGY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCGYABBV
Forward yield2000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$1.6247481716182984e+23M$102.3K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$24,771.77
Total dividends collected$1.6146053563276882e+23M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCGY vs ABBV ($10,000, DRIP)

YearCCGY PortfolioCCGY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,550$430.00+$100.00MCCGY
2$467,446,731,075$467,339,719,626.17$13,472$627.96+$467446.72MCCGY
3$1,021,215,363,816,662$1,020,715,195,814,411.90$15,906$926.08+$1021215363.80MCCGY
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$19,071$1,382.55+$1043112617104.09MCCGY
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$23,302$2,095.81+$498482143759731.38MCCGY
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$29,150$3,237.93+$111599275650097776.00MCCGY
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$37,536$5,121.41+$11738678336351557632.00MCCGY
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$50,079$8,338.38+$583674362697175072768.00MCCGY
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$69,753$14,065.80+$1.3894210989607547e+22MCCGY
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$102,337$24,771.77+$1.6247481716182984e+23MCCGY

CCGY vs ABBV: Complete Analysis 2026

CCGYStock

China Clean Energy Inc., through its subsidiaries, engages in the development, manufacture, and distribution of biodiesel and specialty chemical products made from renewable resources. The company refines biodiesel from waste vegetable oils and waste grease. It also manufactures and sells various industrial chemical products, including polyamide hot-melt adhesives, printing inks, and alcohol and benzene-soluble polyamide resins, as well as various fatty acids, such as dimer, stearic, and monomer acids. The company sells its biodiesel products to service stations and power generating plants in the People's Republic of China; and specialty chemical products to companies in the People's Republic of China, Europe, the United States, and Asia. China Clean Energy Inc. was founded in 1995 and is headquartered in Fuqing, China.

Full CCGY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCGY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCGY vs SCHDCCGY vs JEPICCGY vs OCCGY vs KOCCGY vs MAINCCGY vs JNJCCGY vs MRKCCGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.